bifidobacterium longum

bifidobacterium longum is a live probiotic bacterial drug candidate and microbiome therapeutic consisting of the species *Bifidobacterium longum*. It is being studied primarily as an orally administered microbial therapy intended to modulate the gut microbiota, strengthen epithelial barrier function, reduce inflammatory signaling, and alter host immune and metabolic responses through production of microbial metabolites and interactions with mucosal immune pathways. The exact pharmacology is strain-dependent, and the literature provided includes use in obesity-related metabolic dysfunction, atopic dermatitis models, nonalcoholic steatohepatitis, ulcerative colitis, chronic kidney disease-related uremic toxin reduction, constipation, migraine, ovarian cancer-associated paraneoplastic thrombocythemia, and other exploratory settings. Because the queried name refers to the species broadly rather than a single proprietary strain, it should be treated as a nonspecific live biotherapeutic/probiotic entity rather than one uniquely defined commercial asset.

Brand names

昶乐康

Other names

Bifidobacterium longum长双歧杆菌